Dengue Fever
Conditions
Keywords
Live Attenuated Tetravalent Dengue Vaccine
Brief summary
The purpose of this study is to evaluate the safety and immune response of a naturally aged lot of tetravalent dengue vaccine (TDV) in healthy participants, aged 18 to 60 years, in non-endemic country(ies) for dengue.
Detailed description
The vaccine being tested in this study is tetravalent dengue vaccine (TDV). The primary objective of this study is to evaluate the immune response and safety of a naturally aged (\>12 months stored at 2°C to 8°C) lot of TDV in a healthy adult population in country(ies) non-endemic for dengue. The assessment of a naturally aged lot of TDV in this clinical trial will provide an important contribution to data on TDV stability throughout the shelf life of the product. The study will enroll approximately 200 participants. Participants will be enrolled to the one treatment group: Tetravalent Dengue Vaccine (TDV) All participants will receive subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). This multi-center trial will be conducted in the United States. The overall time to participate in this study is 9 months. Participants will make multiple visits to the clinic including a final visit at Day 270 (Month 9).
Interventions
BIOLOGICALTetravalent Dengue Vaccine (TDV)
TDV SC injection.
Sponsors
Takeda
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
1. Participants who are in good health at the time of entry into the trial as determined by medical history, physical examination (including vital signs), and the clinical judgment of the investigator. 2. Participants who sign and date a written informed consent form and any required privacy authorization prior to the initiation of any trial procedures, after the nature of the trial has been explained according to local regulatory requirements.
Exclusion criteria
1. Participants with a clinically significant active infection (as assessed by the investigator) or body temperature ≥38°C (≥100.4°F) within 3 days of the intended date of vaccine administration 2. Known or suspected impairment/alteration of immune function, including: 1. Chronic use of oral steroids (equivalent to 20 mg/day prednisone ≥12 weeks and/or ≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0) (use of inhaled, intranasal, or topical corticosteroids is allowed). 2. Receipt of parenteral steroids (equivalent to 20 mg/day prednisone ≥12 weeks and/or ≥2 mg/kg body weight/day prednisone ≥2 weeks) within 60 days prior to Day 1 (Month 0). 3. Administration of immunoglobulins and/or any blood products within the 3 months prior to Day 1 (Month 0) or planned administration during the trial. 4. Receipt of immunostimulants within 60 days prior to Day 1 (Month 0). 5. Immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within 6 months prior to Day 1 (Month 0). 6. Known Human Immunodeficiency Virus (HIV) infection or HIV-related disease. 7. Hepatitis C virus infection. 8. Genetic immunodeficiency. 3. With Body Mass Index (BMI) greater than or equal to 35 kg/m\^2(=weight in kg/height in meters\^2). 4. Participants who have known hypersensitivity or allergy to any of the vaccine components. 5. Previous and planned vaccination (during the trial conduct), against any flavivirus including dengue, Yellow Fever (YF), Japanese Encephalitis (JE) viruses or tick-borne encephalitis. 6. Previous participation in any clinical trial of a dengue or other flavivirus (e.g., West Nile \[WN\] virus) candidate vaccine, except for participants who received placebo in those trials. 7. With a current or previous infection with a flavivirus such as dengue, Zika, YF, JE, WN fever, tick-borne encephalitis or Murray Valley encephalitis and participants with a history of prolonged (≥1 year) habitation in a dengue endemic area. 8. Participants with any history of progressive or severe neurologic disorder, seizure disorder or neuro-inflammatory disease (e.g., Guillain-Barré syndrome). 9. Participants with history of substance or alcohol abuse within the past 2 years. 10. Participants who have any serious chronic or progressive disease according to judgment of the Investigator (e.g., neoplasm, insulin dependent diabetes, cardiac, renal or hepatic disease).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 | One month post second dose (Day 120) | GMTs of neutralizing antibodies for each of the 4 dengue serotypes were measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3, and DENV-4. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270 | One month and six months post second dose (Days 120 and 270) | Seropositivity rate was defined as the percentage of participants being seropositive, derived from titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositivity for multiple dengue serotypes was summarized in the following categories: tetravalent and at least trivalent. |
| Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 | Six months post second dose (Day 270) | GMTs of neutralizing antibodies were assessed for the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50. |
| Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | Up to 7 days (Day of vaccination + 6 subsequent days) after each of the vaccination | Solicited local adverse events (AEs) \[at injection site\] were collected by participants using diary cards within 7 days after each vaccination and included injection site pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\], injection site erythema \[Grade 0 (\<25 mm), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\] and injection site swelling \[Grade 0 (\<25 mm), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. The percentages were rounded off to the first decimal place. Only categories with at least 1 participant are reported. |
| Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | One month and six months post second dose (Days 120 and 270) | Seropositivity rate was defined as the percentage of participants being seropositive, derived from titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10 (for each serotype). Seropositivity rates were assessed for the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. |
| Percentage of Participants With Any Unsolicited Adverse Events Following Each Vaccination | Up to 28 days after each vaccination (Day of vaccination + 27 subsequent days) | An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration. |
| Percentage of Participants With Serious Adverse Events (SAEs) | From first vaccination (Day 1) through end of study (Day 270) | An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, leads to a congenital anomaly / birth defect in the offspring of a participant, or is an important medical event which may require intervention to prevent the items listed above or may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization. |
| Percentage of Participants With Medically Attended Adverse Events (MAAEs) | From first vaccination (Day 1) through end of study (Day 270) | MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria. |
| Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | Up to 14 days (Day of vaccination + 13 subsequent days) after each vaccination | Solicited systemic AEs were collected by participants using diary cards within 14 days after each vaccination and included fever, headache, asthenia, malaise and myalgia. Severity grades were: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). Fever is defined as body temperature greater than or equal to 38°C (100.4°F). Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place. Only categories with at least 1 participant are reported. |
Countries
United States
Participant flow
Recruitment details
Participants took part in the study at 2 investigative sites in the United States from 28 March 2019 to 13 March 2020.
Pre-assignment details
Healthy participants were enrolled in this study to receive Tetravalent Dengue Vaccine (TDV) on Days 1 and 90.
Participants by arm
| Arm | Count |
|---|---|
| Tetravalent Dengue Vaccine (TDV) TDV 0.5 mL, injection, subcutaneously (SC), once on Day 1 (first dose) and Day 90 (second dose). | 200 |
| Total | 200 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 22 |
| Overall Study | Withdrawal of Consent | 10 |
Baseline characteristics
| Characteristic | Tetravalent Dengue Vaccine (TDV) |
|---|---|
| Age, Continuous | 40.27 years STANDARD_DEVIATION 12.035 |
| Body Mass Index (BMI) | 27.45 kg/m^2 STANDARD_DEVIATION 4.248 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 64 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 136 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Height | 170.72 cm STANDARD_DEVIATION 9.33 |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 5 Participants |
| Race (NIH/OMB) Black or African American | 41 Participants |
| Race (NIH/OMB) More than one race | 3 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 2 Participants |
| Race (NIH/OMB) White | 148 Participants |
| Region of Enrollment United States | 200 Participants |
| Sex: Female, Male Female | 101 Participants |
| Sex: Female, Male Male | 99 Participants |
| Weight | 80.23 kg STANDARD_DEVIATION 15.22 |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 200 |
| other Total, other adverse events | 0 / 200 |
| serious Total, serious adverse events | 5 / 200 |
Outcome results
Primary
Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120
GMTs of neutralizing antibodies for each of the 4 dengue serotypes were measured by microneutralization test 50% \[MNT50\]. The 4 dengue virus serotypes were DENV-1, DENV-2, DENV-3, and DENV-4.
Time frame: One month post second dose (Day 120)
Population: Per-protocol Set (PPS) excludes all participants seropositive for dengue virus at Baseline and includes all participants in the Full Analysis Set (FAS- who received at least 1 dose of trial vaccine with valid pre-dose and post-dose measurement for immunogenicity assessment) who have no major protocol violations, with data available for analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 | DENV-1 | 557.4 titer |
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 | DENV-2 | 2047.4 titer |
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 | DENV-3 | 131.8 titer |
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMT) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 120 | DENV-4 | 119.6 titer |
Secondary
Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270
GMTs of neutralizing antibodies were assessed for the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4, by MNT50.
Time frame: Six months post second dose (Day 270)
Population: PPS excludes all participants seropositive for dengue virus at Baseline and includes all participants in the FAS who have no major protocol violations, with data available for analysis.
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 | DENV-3 | 63.0 titer |
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 | DENV-4 | 57.6 titer |
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 | DENV-1 | 311.6 titer |
| Tetravalent Dengue Vaccine (TDV) | Geometric Mean Titers (GMTs) of Neutralizing Antibodies for Each of the 4 Dengue Serotypes at Day 270 | DENV-2 | 1170.6 titer |
Secondary
Percentage of Participants With Any Unsolicited Adverse Events Following Each Vaccination
An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a study vaccine; it does not necessarily have to have a causal relationship with study vaccine administration.
Time frame: Up to 28 days after each vaccination (Day of vaccination + 27 subsequent days)
Population: Safety Set included all participants who received at least 1 dose of TDV trial vaccine. Number analyzed is the number of participants with data available for the specific category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Any Unsolicited Adverse Events Following Each Vaccination | After First Vaccination | 11.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Any Unsolicited Adverse Events Following Each Vaccination | After Second Vaccination | 10.8 percentage of participants |
Secondary
Percentage of Participants With Medically Attended Adverse Events (MAAEs)
MAAEs are defined as AEs leading to an unscheduled visit to or by a healthcare professional, including visits to an emergency department, but not fulfilling seriousness criteria.
Time frame: From first vaccination (Day 1) through end of study (Day 270)
Population: Safety Set included all participants who received at least 1 dose of TDV trial vaccine.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Medically Attended Adverse Events (MAAEs) | 26.0 percentage of participants |
Secondary
Percentage of Participants With Serious Adverse Events (SAEs)
An SAE is defined as any untoward medical occurrence that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, leads to a congenital anomaly / birth defect in the offspring of a participant, or is an important medical event which may require intervention to prevent the items listed above or may expose the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization.
Time frame: From first vaccination (Day 1) through end of study (Day 270)
Population: Safety Set included all participants who received at least 1 dose of TDV trial vaccine.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Serious Adverse Events (SAEs) | 2.5 percentage of participants |
Secondary
Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity
Solicited local adverse events (AEs) \[at injection site\] were collected by participants using diary cards within 7 days after each vaccination and included injection site pain \[Grade 0 (no pain), 1 (mild: no interference with daily activity), 2 (moderate: interference with daily activity with or without treatment) and 3 (severe: prevents daily activity with or without treatment)\], injection site erythema \[Grade 0 (\<25 mm), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\] and injection site swelling \[Grade 0 (\<25 mm), 1 (25 - ≤ 50 mm), 2 (\>50 - ≤ 100 mm), 3 (\> 100 mm)\]. The percentages were rounded off to the first decimal place. Only categories with at least 1 participant are reported.
Time frame: Up to 7 days (Day of vaccination + 6 subsequent days) after each of the vaccination
Population: Safety Set included all participants who received at least 1 dose of TDV trial vaccine. Number analyzed is the number of participants with data available for the specific category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Any Solicited Local AEs | 35.9 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Pain: Any Severity | 29.7 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Pain: Mild | 25.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Pain: Moderate | 3.6 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Pain: Severe | 0.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Erythema: Any Severity | 13.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Erythema: Mild | 12.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Erythema: Moderate | 1.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Swelling: Any Severity | 4.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After First Vaccination, Swelling: Mild | 4.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Any Solicited Local AEs | 32.3 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Pain: Any Severity | 31.1 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Pain: Mild | 27.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Pain: Moderate | 2.4 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Pain: Severe | 1.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Erythema: Any Severity | 6.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Erythema: Mild | 6.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Swelling: Any Severity | 2.4 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Local (Injection Site) Reactions Following Each Vaccination by Severity | After Second Vaccination, Swelling: Mild | 2.4 percentage of participants |
Secondary
Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity
Solicited systemic AEs were collected by participants using diary cards within 14 days after each vaccination and included fever, headache, asthenia, malaise and myalgia. Severity grades were: Grade 0: none, Grade 1: mild (no interference with daily activity), Grade 2: moderate (interference with daily activity with or without treatment), Grade 3: severe (prevents normal daily activity with or without treatment). Fever is defined as body temperature greater than or equal to 38°C (100.4°F). Fever was excluded from the overall count as no severity grading was applied for it. The percentages were rounded off to the first decimal place. Only categories with at least 1 participant are reported.
Time frame: Up to 14 days (Day of vaccination + 13 subsequent days) after each vaccination
Population: Safety Set included all participants who received at least 1 dose of TDV trial vaccine. Number analyzed is the number of participants with data available for the specific category.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Any Solicited Systemic Local AEs | 42.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Headache: Any Severity | 30.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Headache: Mild | 22.9 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Headache: Moderate | 5.7 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Headache: Severe | 1.6 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Myalgia: Any Severity | 25.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Myalgia: Mild | 20.8 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Myalgia: Moderate | 3.1 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Myalgia: Severe | 1.6 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Asthenia: Any Severity | 16.7 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Asthenia: Mild | 10.4 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Asthenia: Moderate | 5.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Asthenia: Severe | 1.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Malaise: Any Severity | 19.8 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Malaise: Mild | 13.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Malaise: Moderate | 4.7 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Malaise: Severe | 2.1 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Fever: Any | 2.6 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Fever: 38.0-<38.5 | 2.1 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After First Vaccination, Fever: 38.5-<39.0 | 0.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Any Solicited Systemic Local AEs | 34.1 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Headache: Any Severity | 22.8 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Headache: Mild | 16.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Headache: Moderate | 5.4 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Headache: Severe | 1.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Myalgia: Any Severity | 22.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Myalgia: Mild | 20.4 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Myalgia: Moderate | 1.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Myalgia: Severe | 0.6 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Asthenia: Any Severity | 12.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Asthenia: Mild | 7.8 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Asthenia: Moderate | 3.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Asthenia: Severe | 1.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Malaise: Any Severity | 13.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Malaise: Mild | 9.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Malaise: Moderate | 3.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Malaise: Severe | 1.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Fever: Any | 1.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Fever: 38.0-<38.5 | 0.6 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Percentage of Participants With Solicited Systemic Adverse Events Following Each Vaccination by Severity | After Second Vaccination, Fever: 38.5-<39.0 | 0.6 percentage of participants |
Secondary
Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270
Seropositivity rate was defined as the percentage of participants being seropositive, derived from titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10 (for each serotype). Seropositivity rates were assessed for the four dengue serotypes: DENV-1, DENV-2, DENV-3, and DENV-4.
Time frame: One month and six months post second dose (Days 120 and 270)
Population: The PPS excludes all participants seropositive for dengue virus at Baseline and includes all participants in the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 120: DENV-1 | 99.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 120: DENV-2 | 100.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 120: DENV-3 | 97.7 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 120: DENV-4 | 99.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 270: DENV-1 | 97.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 270: DENV-2 | 98.5 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 270: DENV-3 | 85.7 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Each of the 4 Dengue Serotypes at Days 120 and 270 | Day 270: DENV-4 | 86.5 percentage of participants |
Secondary
Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270
Seropositivity rate was defined as the percentage of participants being seropositive, derived from titers of dengue-neutralizing antibodies. Seropositivity was defined as a reciprocal neutralizing titer ≥10. The dengue virus serotypes are DENV-1, DENV-2, DENV-3 and DENV-4. Seropositivity for multiple dengue serotypes was summarized in the following categories: tetravalent and at least trivalent.
Time frame: One month and six months post second dose (Days 120 and 270)
Population: The PPS excludes all participants seropositive for dengue virus at Baseline and includes all participants in the FAS who have no major protocol violations. Number analyzed is the number of participants with data available for analysis at the given time point.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270 | Day 120: At Least Trivalent | 99.2 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270 | Day 120: Tetravalent | 97.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270 | Day 270: At Least Trivalent | 91.0 percentage of participants |
| Tetravalent Dengue Vaccine (TDV) | Seropositivity Rates for Multiple (2, 3, or 4) Dengue Serotypes at Days 120 and 270 | Day 270: Tetravalent | 78.9 percentage of participants |